These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30238372)

  • 1. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010.
    Mason C; Manzotti E
    Regen Med; 2010 May; 5(3):307-13. PubMed ID: 20455641
    [No Abstract]   [Full Text] [Related]  

  • 8. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Same but Different: Regulation of Tissue Engineering and Regenerative Medicine in the Context of Regional and International Standards and Expectations.
    Williams DF
    Tissue Eng Part A; 2015 Dec; 21(23-24):2781-2. PubMed ID: 26486499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From in vitro to in situ tissue engineering.
    Sengupta D; Waldman SD; Li S
    Ann Biomed Eng; 2014 Jul; 42(7):1537-45. PubMed ID: 24809723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell Therapy Regulatory Toolkit: an online regulatory resource.
    Culme-Seymour EJ; Davies JL; Hitchcock J; Mason J; Carpenter MK; Mason C
    Regen Med; 2015; 10(5):531-4. PubMed ID: 26237697
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products.
    Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S
    Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory issues in cellular therapies.
    Gee AP
    Expert Opin Biol Ther; 2003 Jul; 3(4):537-40. PubMed ID: 12831359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing challenges in regenerative medicine.
    Martin I; Simmons PJ; Williams DF
    Sci Transl Med; 2014 Apr; 6(232):232fs16. PubMed ID: 24739757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA regulation of allogeneic islets as a biological product.
    Weber DJ
    Cell Biochem Biophys; 2004; 40(3 Suppl):19-22. PubMed ID: 15289639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Translation of Regenerative Therapies.
    Allickson JG
    Clin Pharmacol Ther; 2017 Jan; 101(1):28-30. PubMed ID: 27806427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.